Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Apatinib + carboplatin + paclitaxel is a combination therapy regimen that combines a selective VEGFR-2 inhibitor (apatinib) with two chemotherapy agents (carboplatin and paclitaxel). This combination has been studied primarily as a neoadjuvant treatment for locally advanced triple-negative breast cancer (TNBC). Clinical studies have shown promising efficacy with manageable adverse events. The regimen is typically administered in a dose-dense schedule, with apatinib given daily and chemotherapy administered in cycles.
02
Targets
MicrotubuleVEGFR2 (Vascular endothelial growth factor receptor 2)DNA
Beyond the preview
Go deeper on apatinib + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + carboplatin + paclitaxel.